220145-21-1

Usage

Uses

Used in Pharmaceutical Research:
1-((tert-butoxy)carbonylamino)methyl)cyclobutane-1-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential applications in treating different medical conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-((tert-butoxy)carbonylamino)methyl)cyclobutane-1-carboxylic acid serves as a valuable building block for designing and creating novel molecules with specific biological activities. Its versatility in chemical reactions enables the exploration of new therapeutic agents.
Used in Organic Synthesis:
As a cyclobutane derivative with a tert-butoxy carbonyl group, 1-((tert-butoxy)carbonylamino)methyl)cyclobutane-1-carboxylic acid is utilized in organic synthesis to create a wide range of chemical products. Its reactivity and functional groups make it a useful component in the development of new organic compounds for various applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 205173-66-6 1-(aminomethyl)cyclobutanecarboxylic acid 
• 1172902-07-6 (1-(methoxycarbonyl)cyclobutyl)methanaminium chloride 
• 1027337-70-7 1-(aminomethyl)cyclobutanecarboxylic acid methyl ester 
• 58920-79-9 1-Cyan-1-methoxycarbonyl-cyclobutan 

Relevant academic research and scientific papers

4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.

SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN

The disclosure is directed to compounds of Formula I (I) Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.

Preparation and structure of β-peptides consisting of geminally disubstituted β2,2- and β3,3-amino acids: A turn motif for β- peptides

We report on the synthesis of new and previously described β-peptides (1-6), consisting of up to twelve β2,2- or β3,3-geminally disubstituted β-amino acids which do not fit into any of the secondary structural patterns of β-peptides, hitherto disclosed. The required 2,2- and 3,3-dimethyl derivatives of 3-aminopropanoic acid are readily obtained from 3-methylbut-2-enoic acid and ammonia (Scheme 1) and from Boc-protected methyl 3-aminopropanoate by enolate methylation (Scheme 2). Protected (Boc for solution-, Fmoc for solid-phase syntheses) 1- (aminomethyl)cycloalkanecarboxylic-acid derivatives (with cyclopropane, cyclobutane, cyclopentane, and cyclohexane rings) are obtained from 1- cyanocycloalkanecarboxylates and the corresponding dihaloalkanes (Scheme 3). Fully 13C- and 15N-labeled 3-amino-2,2-dimethylpropanoic-acid derivatives were prepared from the corresponding labeled precursors (see asterixed formula numbers and Scheme 4). Coupling of these amino acids was achieved by methods which we had previously employed for other β-peptide syntheses (intermediates 18-23). Crystal structures of Boc-protected geminally disubstituted amino acids (16a-d) and of the corresponding tripeptide (23a), as well as NMR and IR spectra of an isotopically labeled β-hexapeptide (2a*) are presented (Figs. 1-4) and discussed. The tripeptide structure contains a ten-membered H-bonded ring which is proposed to be a turn-forming motif for β-peptides (Fig. 2).